Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mei Jun is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, representing a concentrated prosecution pipeline. This singular focus indicates that the company's current intellectual property efforts are localized within a specific technical classification.
VOLKOV, ALEXANDER ALEXANDROVIC is the busiest examiner for the portfolio, with 1 pending office action under review. As the busiest examiner pending count of 1 matches the total pending office actions, this examiner is the sole individual responsible for the company's active cases. This requires a prosecution approach that is highly responsive to the specific feedback of this examiner. Practitioners should also account for the specific examination trends within the 1 distinct art unit where the case is situated.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VOLKOV, ALEXANDER ALEXANDROVIC | 1 | 29.5% | +21.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17612126 | TEST PIECE FOR RAPID AND QUANTITATIVE DETECTION OF TISSUE CELL PROTEINS | VOLKOV, ALEXANDER ALEXANDROVIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17612126 | TEST PIECE FOR RAPID AND QUANTITATIVE DETECTION OF TISSUE CELL PROTEINS | VOLKOV, ALEXANDER ALEXANDROVIC | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17612126 | TEST PIECE FOR RAPID AND QUANTITATIVE DETECTION OF TISSUE CELL PROTEINS | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §103§112 | Final Rejection | — | Pending | Nov 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMei Jun has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexander Alexandrovic Volkov has the most, with 1 of Mei Jun's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
